Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period

Tomasz Pertyński; Grzegorz Stachowiak

Abstract

1/2008 vol. 7

Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period

Tomasz Pertyński

,

Grzegorz Stachowiak

Przegląd Menopauzalny 2008; 1: 1–8

Online publish date: 2008/03/03

View full text

AMA

Pertyński T, Stachowiak G. Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period. Menopause Review/Przegląd Menopauzalny. 2008;7(1):1-8.

APA

Pertyński, T., & Stachowiak, G. (2008). Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period. Menopause Review/Przegląd Menopauzalny, 7(1), 1-8.

Chicago

Pertyński, Tomasz, and Grzegorz Stachowiak. 2008. "Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period". Menopause Review/Przegląd Menopauzalny 7 (1): 1-8.

Harvard

Pertyński, T., and Stachowiak, G. (2008). Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period. Menopause Review/Przegląd Menopauzalny, 7(1), pp.1-8.

MLA

Pertyński, Tomasz et al. "Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period." Menopause Review/Przegląd Menopauzalny, vol. 7, no. 1, 2008, pp. 1-8.

Vancouver

Pertyński T, Stachowiak G. Estradiol together with dydrogesterone in oral hormonal therapy of the menopausal period. Menopause Review/Przegląd Menopauzalny. 2008;7(1):1-8.

Estradiol (E2) and dydrogesterone have been present in oral hormone therapy (HT) of the menopausal period for some years. E2/dydrogesterone preparations attainable in Poland at present show high therapeutic efficacy both as continuous (including low-dose) and sequential HT. This oestrogen-progestogen combination is characterized by an exceptionally advantageous pharmacological profile (with a favourable influence on lipid profile, carbohydrate metabolism, blood pressure or skin) and high therapeutic safety (an impact on endometrium, uterine bleeding profile and breast tissues). This type of HT should be one of the basic therapeutic options for menopausal women in need of hormonal treatment.